Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, reviews the recent updates to the National Comprehensive Cancer Network (NCCN) Guidelines for systemic mastocytosis. Dr Gerds emphasizes the need to consult the most up-to-date version of the guidelines when treating patients.
Distinguishing indolent from advanced systemic mastocytosis is notoriously complex, even for seasoned clinicians. To simplify diagnosis, researchers developed a mathematical model using basic lab values, achieving 93% predictive…
In an expert roundtable discussion, Matthew P. Giannetti, MD, Harvard Medical School, Brigham and Women’s Hospital Mastocytosis Center, Boston, Massachusetts; Lauren M. Madigan, MD, University of Utah, University…
In an interview conducted at the 2025 European Society for Blood and Marrow Transplantation Annual Meeting, Deepti Radia, MBBS, BSc, MRCPI, FRCPath, MSc Med Ed, Guy’s and St…
Surgeon Commander VA Arun, INHS Asvini, Colaba, Mumbai, and Anil Handoo, MD, BLK-Max Superspeciality Hospital, Delhi, discuss systemic mastocytosis. They review classification and diagnostic criteria and the clinical…
Presented by the Florida Society of Clinical Oncology, this program provides opportunities for patients and caregivers to learn and share information regarding a diagnosis of systemic mastocytosis. Pankit…
